Robin Gasiorowski

8PUBLICATIONS

49CO-AUTHORS

Molecular targetsInstruments and techniquesPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (8)

Sort by Publication Date:

|Aug 25, 2026

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

|Jan 28, 2025

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

Harry J Iland, John Reynolds, Alan V Boddy

|Sep 25, 2024

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.

Catherine Thieblemont, Yasmin H Karimi, Herve Ghesquieres

|Dec 22, 2022

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Catherine Thieblemont, Tycel Phillips, Herve Ghesquieres

|Apr 23, 2022

Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.

Jonathan Wong, Emily Gruber, Belinda Maher

|Oct 13, 2021

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.

Pier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro

Pageof 2

Frequent Collaborators

Judith Trotman

Chan Y Cheah

Michael Dickinson

Tae Min Kim

Catherine Thieblemont

John Reynolds

Pietro Di Ciaccio

Ryan A Wilcox

Greg Hapgood

Pier Luigi Zinzani

Frequent Collaborators

Judith Trotman

Chan Y Cheah

Michael Dickinson

Tae Min Kim